1xbet 보너스 코드 Pharmaceutical Co., Ltd.
Pharmaceuticals
May 30, 2022
Launch 1xbet 보너스 코드 Japan of SAMTASU®1xbet 보너스 코드 IV Infusion,
a V2-Receptor Antagonist 1xbet 보너스 코드 the Treatment of Cardiac Edema
1xbet 보너스 코드 Pharmaceutical Co., Ltd. (1xbet 보너스 코드) announces that a V2-receptor antagonist 1xbet 보너스 코드 the treatment of cardiac edema, SAMTASU®8 mg and 16 mg 1xbet 보너스 코드travenous 1xbet 보너스 코드fusion, has been launched 1xbet 보너스 코드 Japan on May 30, 2022.
SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body following administration. Tolvaptan, discovered by 1xbet 보너스 코드, is a novel compound that is as an antagonist of the vasopressin V2-receptor. It inhibits water reabsorption at the renal collecting duct, thereby enhancing water diuresis (aquaresis) without depletion of electrolytes. Until now, tolvaptan has been available only in oral 1xbet 보너스 코드m.
SAMTASU is an intravenous diuretic that provides a new treatment option 1xbet 보너스 코드 patients with fluid retention who have difficulty receiving tolvaptan orally.
Latest Pharmaceutical Bus1xbet 보너스 코드ess related News Releases